All In MedTech

FDA Clearance Tracker · P130021-S174

Evolut PRO+ System, Evolut FX System, Evolut FX+ System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Aug 27, 2025 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Aug 27, 2025

Approved

Time to decision

180 days

Received Feb 28, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P130021-S174
Device name
Evolut PRO+ System, Evolut FX System, Evolut FX+ System
Applicant location
Miinneapolis, MN
Received
Feb 28, 2025
Decided
Aug 27, 2025
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P130021

Device type

Device class
Class III

Every decision under product code NPT

FDA's approval statement

As written in FDA's record.

Approval for the Evolut PRO+ System, Evolut FX System, Evolut FX+ System for expanding the indications to include the treatment of patients with a failed trascatheter aortic valve who are at high or greater risk of mortality from open surgical therapy. This device is indicated for use in patients with symptomatic heart disease due to failure (stenosed, insufficient, or combined) of a surgical or transcatheter bioprosthetic aortic valve who are judged by a heart team, including a cardiac surgeon, to be at high or greater risk for open surgical therapy (i.e., predicted risk of surgical mortality >8% at 30 days, based on the STS risk score and other clinical co-morbidities unmeasured by the STS risk calculator).

Source documents

Other decisions for Medtronic, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.